Scientists develop free computer program to map blood flow 'landscape' in tumors

March 05, 2020

Johns Hopkins Medicine researchers have created a computer program for scientists at no charge that lets users readily quantify the structural and functional changes in the blood flow networks feeding tumors.

The researchers published a link to download the new program, called HemoSYS, and an accompanying manual with instructions on how to use it, on Feb. 11 in Scientific Reports.

"Compared to blood flow in healthy tissues, tumor blood flow is abnormal, and these abnormalities can be captured with new imaging methods. Therefore, we created a freely available toolkit called HemoSYS that enables scientists to quantify these abnormalities from imaging data acquired from tumors in live animals", says Arvind Pathak, Ph.D., associate professor of radiology and biomedical engineering at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

Studying the architecture of blood vessels and their flow dynamics in tumors could provide insights into cancer progression and metastasis, says Janaka Senarathna, Ph.D., a research fellow in Pathak's lab and lead author of the paper. This approach could accelerate development of new therapies that target a tumor's blood vessels in order to limit its supply of nutrients and oxygen. HemoSYS could also lead to more effective delivery of already available drugs by mapping blood flow fluctuations in the vessels feeding the tumor.

A tumor's blood vessels are its lifeline for survival and growth, providing it with nutrients as well as an avenue for tumor cells to spread to other parts of the body. However, these vessels often grow irregularly and create abnormal blood flow patterns, making them a huge hurdle to effective delivery of therapeutics.

"The abnormal blood flow makes it difficult to predict how effective therapies will be, and if insufficient drug is delivered to the tumor, cancers may recur or develop resistance to treatment or advance harmful side effects," says Pathak.

The Johns Hopkins investigators caution that the research tool is not directly applicable to human tumors yet. But, says Pathak, "As our ability to obtain high-resolution images in the clinic improves, we hope that this tool can be adapted to provide a noninvasive way to analyze the blood flow fluctuations in an individual patient's cancer and help to customize their therapy."

To develop HemoSYS, the Pathak Lab recruited biomedical engineers and biophysicists to develop accurate, efficient ways to quantify "multivariable" data comprised of tumor blood flow, blood volume and oxygenation images. A different type of light source was used to collect each of these data variables from tumors implanted in animals.

"Typically, a research lab studying these blood vessel systems would need to have extensive expertise in image processing to quantify the relationships between these measurements," says Pathak. "HemoSYS allows researchers without any programming expertise to conduct their analyses on these multivariable imaging data."

The HemoSYS program employs fundamental engineering principles to analyze and integrate different kinds of data collected from various imaging methods.

This data enables scientists to rigorously map the entire "hemodynamic landscape" of the tumor being studied, says Pathak. The result is a colorful yet informative visualization that shows the relationships among blood flow, oxygenation and tumor cells in vivid reds, blues and greens.

"The system lets researchers see that there may be an area in the tumor of low oxygen supply caused by poor blood flow, or see that an area is low on oxygen even though it's exhibiting elevated blood volume," says Pathak.

Scientists and clinicians can download the toolkit at Pathak and his team have also made a customizable version for those who want to adapt HemoSYS for their own experiments or for data acquired with other imaging methods such as MRI, ultrasound and dynamic CT.
Other researchers involved in this study include Ayush Prasad, Akanksha Bhargava, Stacy Gil and Nitish Thakor of the Johns Hopkins University School of Medicine.

This work was supported by the National Cancer Institute (1R01CA196701, 5R01CA138264) and a Kavli Neuroscience Distinguished Fellowship.

The authors declare no competing interests.

Johns Hopkins Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to